[voir l'étude complète
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1599741
ce pourrait être intéressant de refaire l'étude dans les pays où plus de 80 produits à base des dérivés de l'artémeter sont enregistrés...CB]
Malar J. 2006; 5: 81.
Published online 2006 October 4. doi: 10.1186/1475-2875-5-81.
PMCID: PMC1599741
Copyright © 2006 Jackson et al; licensee BioMed Central Ltd.
Malaria treatment failures after artemisinin-based therapy in three
expatriates: could improved manufacturer information help to decrease the
risk of treatment failure ?
Yves Jackson,corresponding author1 François Chappuis,1 Louis Loutan,1 and
Walter Taylor1,2
1Travel and Migration Medicine Unit, Geneva University Hospital, Rue
Micheli-du-Crest 24, 1211 Geneva 14, Switzerland
2UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in
Tropical Diseases, World Health Organisation, Av. Appia 20, Geneva,
Switzerland
corresponding authorCorresponding author.
Yves Jackson: yves.jackson@hcuge.ch; François Chappuis:
francois.chappuis@hcuge.ch; Louis Loutan: louis.loutan@hcuge.ch; Walter
Taylor: bobtaylor@oucru.netnam.vn
Received March 17, 2006; Accepted October 4, 2006.
Abstract
Background
Artemisinin-containing therapies are highly effective against Plasmodium
falciparum malaria. Insufficient numbers of tablets and inadequate package
inserts result in sub-optimal dosing and possible treatment failure. This
study reports the case of three, non-immune, expatriate workers with P.
falciparum acquired in Africa, who failed to respond to artemisinin-based
therapy. Sub-therapeutic dosing in accordance with the manufacturers'
recommendations was the probable cause.
Method
Manufacturers information and drug content included in twenty-five
artemisinin-containing specialities were reviewed.
Results
A substantial number of manufacturers do not follow current WHO
recommendations regarding treatment duration and doses.
Conclusion
This study shows that drug packaging and their inserts should be improved.